{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:12:51Z","timestamp":1789197171262,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eplepsyres.2026.107852","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:38:39Z","timestamp":1781800719000},"page":"107852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness and safety of brivaracetam in patients with focal epilepsy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6641-721X","authenticated-orcid":false,"given":"Yuchen","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2026.107852_bib1","article-title":"Overnight switch from levetiracetam to brivaracetam. Safety and tolerability","volume":"16","author":"Abraira","year":"2021","journal-title":"Epilepsy Behav. Rep."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib3","article-title":"Brivaracetam add-on therapy for drug-resistant epilepsy","volume":"2019","author":"Bresnahan","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fneur.2018.00969","article-title":"Serum levels of brain-derived neurotrophic factor and insulin-like growth factor 1 are associated with autonomic dysfunction and impaired cerebral autoregulation in patients with Epilepsy","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102513","article-title":"Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials","volume":"70","author":"Chen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40801-021-00246-7","article-title":"Brivaracetam retention rate and seizure outcomes in patients with drug-resistant focal epilepsy included in the medical need program in belgium: a real-world, multicenter, chart review","volume":"8","author":"Depondt","year":"2021","journal-title":"Drugs Real. World Outcomes"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib8","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/epi.17187","article-title":"Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial","volume":"63","author":"Farkas","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109922","article-title":"Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: experience, a pooled analysis of international data from retrospective studies","volume":"158","author":"Faught","year":"2024","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib11","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","article-title":"Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"10","author":"Feigin","year":"2025","journal-title":"Lancet Public. Health"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/epi.13075","article-title":"Dietary therapy is the best option for refractory nonsurgical epilepsy","volume":"56","author":"Felton","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106757","article-title":"Efficacy of Brivaracetam in children with epilepsy","volume":"177","author":"Ferragut Ferretjans","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5698\/1535-7511-12.4s.22","article-title":"AED treatment through different ages: as our brains change, should our drug choices also?: AED treatment through different ages","volume":"12","author":"French","year":"2012","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib16","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1007\/s12325-025-03253-0","article-title":"Safety, tolerability, and efficacy of adjunctive brivaracetam in japanese and chinese patients with focal-onset seizures: interim analysis of a phase 3 open-label extension trial","volume":"42","author":"Fujimoto","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib18","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s10072-025-08185-9","article-title":"Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: a systematic review and meta-analysis","volume":"46","author":"Hassan","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \u201ccommon\u201d neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/epi4.12929","article-title":"Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: a phase iii randomized, double-blind, placebo-controlled trial","volume":"9","author":"Inoue","year":"2024","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12793\/tcp.2021.29.e1","article-title":"A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy","volume":"29","author":"Jeon","year":"2021","journal-title":"Transl. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.2014.17426","article-title":"Resective epilepsy surgery for drug-resistant focal epilepsy: a review","volume":"313","author":"Jobst","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib23","first-page":"74","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the american academy of","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurol. Am. Epilepsy Soc. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib25","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/epi.13340","article-title":"Brivaracetam: rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment","volume":"57","author":"Klitgaard","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17223","article-title":"Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures","volume":"63","author":"Lattanzi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","article-title":"Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis","volume":"86","author":"Lattanzi","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.19003","article-title":"Epilepsy in the elderly: treatment and consideration of comorbid diseases","volume":"9","author":"Lee","year":"2018","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/epi4.12415","article-title":"Brivaracetam substituting other antiepileptic treatments: results of a retrospective study in German epilepsy centers","volume":"5","author":"Lerche","year":"2020","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib33","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1093\/nutrit\/nuac021","article-title":"Ketogenic diet, epilepsy and cognition: what do we know so far? A systematic review","volume":"80","author":"Lima","year":"2022","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib34","first-page":"291","article-title":"Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. pediatr","volume":"21","author":"Liu","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fneur.2020.00813","article-title":"Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study","volume":"11","author":"Maschio","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030746","article-title":"First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study","volume":"9","author":"Menzler","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1059-1311(03)00047-5","article-title":"Measuring the efficacy of antiepileptic drugs","volume":"12","author":"Mohanraj","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010154","article-title":"Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy","volume":"95","author":"Nair","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.819889","article-title":"The clinical characteristics of new-onset epilepsy in the elderly and risk factors for treatment outcomes of antiseizure medications","volume":"13","author":"Qi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.seizure.2025.01.011","article-title":"First clinical post-approval, observational study to assess clinical safety and effectiveness of brivaracetam sustained-release formulation in real-life settings of India: BEAM study","volume":"125","author":"Ranganathan","year":"2025","journal-title":"Seizure Eur. J. Epilepsy"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clinph.2024.04.023","article-title":"Quantitative EEG analysis of brivaracetam in drug-resistant epilepsy: a pharmaco-EEG study","volume":"163","author":"Ricci","year":"2024","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib42","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/epi.17240","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Riney","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/17460441.2017.1366985","article-title":"The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy","volume":"12","author":"Russo","year":"2017","journal-title":"Expert. Opin. Drug. Discov."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36230","article-title":"Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: a meta-analysis","volume":"7","author":"Salcher-Konrad","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.12565","article-title":"Drug-resistant epilepsy and the hypothesis of intrinsic severity: What about the high-frequency oscillations?","volume":"7","author":"Santana-Gomez","year":"2022","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib47","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.15012","article-title":"Clinical and electroencephalography assessment of the effects of brivaracetam in the treatment of drug-resistant focal epilepsy","author":"Savastano","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib48","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/epi4.70073","article-title":"Effectiveness and safety of early add-on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV -add study","volume":"10","author":"Serrano-Castro","year":"2025","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2024-3-2","article-title":"A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: the bravo study","volume":"13","author":"Siddiqui","year":"2024","journal-title":"Drugs Context."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies ( MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1170780","article-title":"Safety and efficacy of brivaracetam in children epilepsy: a systematic review and meta-analysis","volume":"14","author":"Song","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617742081","article-title":"Brivaracetam: a novel antiepileptic drug for focal-onset seizures","volume":"11","author":"Stephen","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib53","first-page":"171","article-title":"Epilepsy in elderly patients: does age of onset make a difference?","volume":"37","author":"Suller Marti","year":"2022","journal-title":"Neurol. Engl. Ed."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib55","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/epi.13416","article-title":"Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures","volume":"57","author":"Toledo","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib56","series-title":"A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact\u00ae (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice (Clinical trial registration No","author":"UCB Biopharma S.P.R.L","year":"2021"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"Van Paesschen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib58","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40272-024-00652-8","article-title":"The effect of levetiracetam and valproic acid treatment on anger and attention deficit hyperactivity disorder clinical features in children and adolescents with epilepsy: a prospective study","volume":"26","author":"Vatansever P\u0131nar","year":"2024","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.eplepsyres.2026.107852_bib59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib60","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12264-023-01138-2","article-title":"Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil","volume":"40","author":"Wu","year":"2024","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib61","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1038\/s41467-024-47322-4","article-title":"Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A","volume":"15","author":"Yamagata","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1716128","article-title":"An evidence-based meta-analysis on the use of brivaracetam in treating seizures in real-world clinical practice","volume":"16","author":"Zhang","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2026.107852_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.seizure.2016.11.008","article-title":"The adverse event profile of brivaracetam: a meta-analysis of randomized controlled trials","volume":"45","author":"Zhu","year":"2017","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121126001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:50:00Z","timestamp":1789195800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121126001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0920121126001221"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107852","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of brivaracetam in patients with focal epilepsy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2026.107852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107852"}}